SOL Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

SOL Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,400	Closed	-$481K	–	272
2025 Q4	$481K	Buy	15,400 +1,300	+9%	+$32K	0.04%	239
2025 Q3	$285K	Hold	14,100	–	–	0.03%	274
2025 Q2	$236K	Hold	14,100	–	–	0.02%	286
2025 Q1	$217K	Hold	14,100	–	–	0.02%	288
2024 Q4	$311K	Hold	14,100	–	–	0.03%	261
2024 Q3	$254K	Hold	14,100	–	–	0.03%	279
2024 Q2	$229K	Hold	14,100	–	–	0.03%	280
2024 Q1	$199K	Hold	14,100	–	–	0.03%	295
2023 Q4	$147K	Hold	14,100	–	–	0.02%	292
2023 Q3	$144K	Hold	14,100	–	–	0.02%	286
2023 Q2	$106K	Buy	14,100 +1,880	+15%	+$15.2K	0.02%	278
2023 Q1	$108K	Hold	12,220	–	–	0.02%	276
2022 Q4	$111K	Sell	12,220 -7,400	-38%	-$64.6K	0.02%	271
2022 Q3	$158K	Sell	19,620 -2,000	-9%	-$17.7K	0.03%	254
2022 Q2	$163K	Sell	21,620 -11,198	-34%	-$97.6K	0.03%	250
2022 Q1	$308K	Sell	32,818 -11,100	-25%	-$92.6K	0.06%	222
2021 Q4	$352K	Hold	43,918	–	–	0.06%	215
2021 Q3	$428K	Sell	43,918 -650	-1%	-$6.09K	0.09%	196
2021 Q2	$441K	Hold	44,568	–	–	0.09%	189
2021 Q1	$514K	Hold	44,568	–	–	0.11%	162
2020 Q4	$430K	Sell	44,568 -2,800	-6%	-$26.8K	0.1%	175
2020 Q3	$427K	Sell	47,368 -2,000	-4%	-$21.2K	0.12%	149
2020 Q2	$609K	Buy	49,368 +150	+0.3%	+$1.7K	0.17%	122
2020 Q1	$442K	Sell	49,218 -2,000	-4%	-$20.5K	0.15%	138
2019 Q4	$502K	Sell	51,218 -41,124	-45%	-$367K	0.13%	161
2019 Q3	$635K	Sell	92,342 -23,875	-21%	-$183K	0.17%	133
2019 Q2	$1.07M	Sell	116,217 -900	-0.8%	-$10.9K	0.29%	95
2019 Q1	$1.84M	Sell	117,117 -4,000	-3%	-$70.5K	0.51%	61
2018 Q4	$1.87M	Sell	121,117 -6,050	-5%	-$124K	0.6%	48
2018 Q3	$2.74M	Sell	127,167 -1,078	-0.8%	-$25K	0.74%	38
2018 Q2	$3.12M	Sell	128,245 -319	-0.2%	-$6.5K	0.89%	25
2018 Q1	$2.2M	Sell	128,564 -3,025	-2%	-$59.1K	0.63%	42
2017 Q4	$2.49M	Buy	131,589 +12,432	+10%	+$187K	0.71%	37
2017 Q3	$2.1M	Buy	119,157 +56,414	+90%	+$1.27M	0.59%	45
2017 Q2	$2.08M	Buy	62,743 +1,050	+2%	+$32.5K	0.57%	46
2017 Q1	$1.98M	Buy	61,693 +5,670	+10%	+$194K	0.56%	46
2016 Q4	$2.03M	Buy	56,023 +21,576	+63%	+$861K	0.61%	40
2016 Q3	$1.58M	Buy	34,447 +1,900	+6%	+$99.1K	0.53%	47
2016 Q2	$1.64M	Sell	32,547 -170	-0.5%	-$9.05K	0.54%	41
2016 Q1	$1.75M	Hold	32,717	–	–	0.59%	39
2015 Q4	$2.15M	Sell	32,717 -200	-0.6%	-$12.4K	0.76%	30
2015 Q3	$1.86M	Sell	32,917 -300	-0.9%	-$19.5K	0.72%	35
2015 Q2	$1.96M	Sell	33,217 -230	-0.7%	-$14.2K	0.72%	37
2015 Q1	$2.08M	Sell	33,447 -350	-1%	-$20.4K	0.77%	27
2014 Q4	$1.94M	Sell	33,797 -319	-0.9%	-$17.8K	0.75%	29
2014 Q3	$1.83M	Sell	34,116 -2,700	-7%	-$143K	0.76%	27
2014 Q2	$1.93M	Sell	36,816 -300	-0.8%	-$15.3K	0.77%	27
2014 Q1	$1.96M	Hold	37,116	–	–	0.77%	25
2013 Q4	$1.49M	Sell	37,116 -350	-0.9%	-$13.8K	0.57%	36
2013 Q3	$1.42M	Sell	37,466 -980	-3%	-$38.2K	0.59%	34
2013 Q2	$1.51M	Buy	+38,446	New	+$1.5M	0.61%	32

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SOL Capital Management's TEVA Position: Q1 2026 in Review

SOL Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 15,400 shares — an estimated $481K sold.

SOL Capital Management first reported a position in TEVA in Q2 2013 and held it in 51 quarters. The position peaked at $3.12M in Q2 2018. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

SOL Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
SOL Capital Management sold 15,400 Teva Pharmaceuticals shares in Q1 2026, an estimated $481K.
SOL Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 51 quarters.
SOL Capital Management's Teva Pharmaceuticals position peaked at $3.12M in Q2 2018.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on SOL Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.